TY  - JOUR

T1  - Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

JO  - JOURNAL OF BONE ONCOLOGY

UR  - https://eprints.whiterose.ac.uk/id/eprint/140820

UR  - https://doi.org/10.1016/j.jbo.2018.09.008

PY  - 2018/11/01

AU  - Coleman RE

AU  - Collinson M

AU  - Gregory W

AU  - Marshall H

AU  - Bell R

AU  - Dodwell D

AU  - Keane M

AU  - Gil M

AU  - Barrett-Lee P

AU  - Ritchie D

AU  - Bowman A et al

ED  - 

DO  - DOI: 10.1016/j.jbo.2018.09.008

PB  - Elsevier

VL  - 13

SP  - 123

EP  - 135

Y2  - 2025/12/05

ER  -